Ram Pyare Singh, M.Sc., Ph.D.

Research Biologist, and Principal Investigator

Immunology and Autoimmunity Laboratory

VA Greater Los Angeles Health System (VAGLAHS)

Member, Interdisciplinary Translational Immunology, UCLA

11301 Wilshire Blvd, Bldg 114, Rm 114, Los Angeles, CA, 90073

TEL: Business: 310-***-**** ext.43836; Cell: 310-***-****;

E-mail: adcr3y@r.postjobfree.com; adcr3y@r.postjobfree.com; adcr3y@r.postjobfree.com

SUMMARY

Ph.D in Biology with post-doctoral training in immunopharmacology, T-cell biology, and cellular and molecular immuno-oncology. Experience in cancer and CAR-T cell biology.

Extensive experience in in vitro and in vivo pharmacologic and immunologic procedures in mouse, rat, and human T cells and subsets and in pre-clinical models.

Development and testing of pre-clinical drugs, biomarkers, and bioassays in the areas of inflammation, autoimmunity, cancer therapeutics (exosomes).

Quality Control (QC/QA) management experience (3 years) in testing of human brain samples/specimens (3 years) at the VA Brain Bank, Veteran Administration Greater Los Angeles HealthCare System.

Excellent skills in all areas of experimental design, developing protocols, SOPs, problem-solving, statistical analysis (EXCELL, PRISM, JUMP), writing scientific reports, data presentation, peer-reviewed publications, and in GDP, GLP, GMP regulations.

Publication of high impact immunological papers in general T-cell biology, Th1/Th17 and T-regulatory cells, immunomodulation, and immune tolerance.

Experience in multitasking, managed goals with defined timeframes, and outstanding team player with strong interpersonal and communication skills.

RESEARCH DISCOVERY & EXPERIENCE

Broad background in cellular immunology and molecular biology with extensive experience in Autoimmune-, Inflammatory-, and Neurology-related Diseases (functional genomics). Research experience in in vitro and in vivo immunologic procedures in mouse, rat, and human cells and pre-clinical models of Lupus, Arthritis, Atherosclerosis, Transplantation, Leprosy, Tuberculosis, and Malaria.

Experience supervising/managing a dynamic research group consisting of graduate and undergraduate students, post-docs, clinical fellows, and research associates/technicians. Managed Animal Review Committee, IRB regulation, clinical trials at University level, and quality assurance/control (QA/QC) data of the VA Brain Bank at VAGLAHS. Experience and knowledge of GLP, GMP and GDP.

Supervised clinical trials with pharmaceutical companies in inflammatory autoimmune diseases in Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) patients.

Publication of high impact papers in immunology, genomics, autoimmunity, immunomodulation, infection, inflammation, neuroscience, brain gene expression, and with regulatory T cells.

EDUCATION

Post-Doctoral Training, University of California at Los Angeles (UCLA), USA, 2000-2003

Research Scientist, ICGEB, Malaria Group, New Delhi, 1999-2000

Visiting STA Scientist (Science and Technology Agency of Japan), Tokyo, 1996-1998

Visiting Scientist, JSPS, University of Tokyo, Japan, 1999-2000

Post-Doctoral Research Associate, Dept. of Biotechnology (Cellular Immunology), All India Institute of Medical Sciences, New Delhi, 1994-1996.

Post-Doctoral Research Associate, Institute of Medical Sciences, BHU, Varanasi, 1992-1994

Ph.D. Pharmacology/Translational Immunology, Institute of Medical Sciences, Banaras Hindu University, (BHU), Varanasi, India, 1991

MSc, Zoology, Gorakhpur University, UP College, Varanasi, India

BS, Biological Science and Chemistry, Gorakhpur University, UP College, Varanasi, India

SKILLS:

Techniques utilized include: SDS-PAGE, Western blot, Immunohistochemistry, AlphaLISA, ELISA, Flow Cytometry, Isolation of RNA/DNA, RNA CHIP analyses assays, RT-PCR, Isolation of primary cells, Cell culture, CTL assays, Immunofluorescence microscopy, Imaging; Immunomodulation with peptides, Validation of target molecules, Infection & immunity, Transplant tolerance, T-cell biology, PH measurement, antibody testing, Brain gene expression mapping, Microarray and microRNA analyses, Animal models, Knockout/ Knock-in/ Knock-down and silencing of genes with siRNA or shRNA, Quality control, and bio-statistical analysis.

CONSULTING WORK EXPERIENCE

NeuroBio Inc 2017 - Present

Developed AlphaLISA immunoassay to analyse tissue from human and mice with Alzheimer’s and Parkinson’s diseases. Pre-clinical drug development.

Seattle Genetics 2007 - 2013

Managed and Developed immunoassays to analyse samples from Rheumatoid Arthritis and Lupus patients.

BMS 2011 - 2014

Analysed the effects of the drug Benlysta-Belimumab in Rheumatoid Arthritis patient samples using immunoassay, immuno-phenotyping, and multicolour flow cytometry.

Advanced Cell Technology Inc 2012 - 2013

Managed and carried out human mesenchymal stem cell adoptive transfer experiments with Lupus mice. Cultured mesenchymal stem cells, cryopreserved and tested their immunomodulatory properties in mice.

RESEARCH EXPERIENCE

Research Biologist, Principal Investigator, VA Greater LA Healthcare System, Los Angeles, Nov 2013-Present.

Developed immunoassays - AlphaLISA, ELISA, pre-clinical drug development. Using flow cytometry, carried out experiments to phenotype T cells from diabetic and Alzheimer’s models of rats/mice and from human PBMC samples. Tested the activity/function of T-cell subsets. Isolated RNA/DNA from human brain samples. Developed ELISA to test for infectious agents in brain tissue. Managed quality assurance and quality control data at VA Brain Bank.

Post-Doctoral-Research and Faculty (Associate Professor/Professor), David Geffen School of Medicine at UCLA Sept 2000-Jun 2013. Peptide research- immune tolerance, immune modulation in autoimmunity, immune-oncology. Isolation and culture of T-cell subsets, B cells, and monocytes. Designed and executed experiments with human and rodent brains. Carried out RNA extraction, RT-PCR, IHC with quantum dots, behavior testing and translational immunology. Conducted basic and clinical research in autoimmunity (lupus) involving stimulation of CD4+ and CD8+ Treg cells. Managed the UCLA Immunology and Autoimmunity Laboratory. Trained students, scientists, research associates, and fellows.

APPOINTMENTS

11/2013-Present Research Biologist, Adjunct Professor, Principal Investigator, Veteran Administration, VA Greater Los Angeles Healthcare System (VAGLAHS).

07/2011-06/2013 Professor Step I, Div. of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, California.

07/2009- 06/2011 Associate Professor Step III, Div. of Rheumatology, Dept. of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.

07/2007-06/2009 Associate Professor Research Step III (Associate Researcher), Div. of Rheumatology, Dept. of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.

11/2003-06/2007 Assistant Professor Research, Step IV (Assistant Researcher), Div. of Rheumatology, Dept. of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.

09/2000–11/2003 Senior Post-Doctoral Researcher, at Immunogenetics Center, and Dept. of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

HONORS

1986 Ph.D. Fellowship award from ICMR (Indian Council of Medical Research), New Delhi.

1987 International Society of Nephrology Travel Fellowship, London, to attend the 10th International Congress of Nephrology in London, UK.

1988 Fellow of International College of Nutrition.

1993 Research Scientist Award, ICMR (Indian Council of Medical Research), New Delhi

1994 Research Associate, Department of Biotechnology, New Delhi, India.

1996 STA International Scientist Award, Science and Technology Agency, Govt. of Japan.

1999 JSPS (Visiting Scientist Award) at Univ. of Tokyo, Japan.

2000 STA Fellow International Scientist Award, Science and Technology Agency, Japan.

2005 American Association of Immunologists (AAI) junior faculty travel award, San Diego, USA.

2006 American Association of Immunologists (AAI) junior faculty travel award, Boston, USA.

2007 American Association of Immunologists (AAI) junior faculty travel award, Miami, USA.

2007 Young Investigator Award (8th International Congress of Lupus, Shanghai).

2007 Recipient of National Institute of Health, (NIAMS R03 AR 054034) award.

2007 Recipient of National Institute of Health, (NAIID R21- AI 065645) award.

2008 American Association of Immunologists (AAI) junior faculty travel award, San Diego, USA.

2009 Recipient of Clinical Translational Seed Program (CTSP) Oppenheimer award, UCLA.

2009 Recipient of Rapid Grant Award, Older American Independence Center (OAIC), UCLA.

2009 Federation of Clinical Immunology Societies (FOCIS) travel award San Francisco, USA.

2010 Biolegend Travel Award to attend XIV International Immunology Congress, Kobe, Japan.

2011 AAI Travel Grant to attend AAI, San Francisco, USA.

2013 American Autoimmune Related Disease Association (AARDA) grant.

2013 American Association of Immunologist Laboratory Travel Grant, Hawaii, USA.

2016 American Association of Immunologist Laboratory Travel Grant AAI, Seattle, WA, USA.

2017 American Association of Immunologist Laboratory Travel Grant to attend AAI, Washington, DC.

2018 American Association of Immunologist Laboratory Travel Grant, Austin. Texas, USA.

2018 Visiting Professor-Faculty, NeuroBio and University of Oxford, UK.

2019 American Association of Immunologist Laboratory Travel Grant to attend AAI, San Diego, USA.

2020 American Association of Immunologist Laboratory Travel Grant to attend AAI, Honolulu Hawaii, USA.

PROFESSIONAL MEMBERSHIPS

American Association for the Advancement of Science (AAAS)

American Association of Immunologists (AAI)

American College of Rheumatology (ACR)

Federation of American Societies of Experimental Biology (FASEB)

Teaching Experience: Medical School Immunology Course, 1990-1994; Graduate School Immunology Course, 1994-2000; Post-Doctoral Fellow, Functional Genomics and Molecular Medicine Course, 2001-2003; Rheumatology Fellows Immunology Course, 2003-2014.

Mentoring: Supervision of four post-graduate students in the Dept. of Biotechnology at the All India Institute of Medical Sciences, New Delhi; Supervision of 2 undergraduate students (K Bhavsar-Medical student, Abhijit J Choudhary-Ph.D candidate) while a post doc at the Dept. of Molecular and Medical Pharmacology at UCLA; Supervision of 1 summer student (Gloricelys Rivera-Velázquez) in the Pharmacology Dept, UCLA; Supervision of several UCLA undergraduate students (Alejandro M Tamayo, Michelle Palacios, Michelle Wray, Paola Rosa Lepe, Dennis Andrew Sambolin, Saranpreet Nagra, Priya Sawla, Vineet Dixit, Jayeeta Manna, Sudhir Manichavel, Israel Massachi, Hamida Rehimi) and two post docs (MD Awlad and S Katsiougiannis) at the UCLA.

Grant Review Committees -Study Sections; Reviewer NIH and others 2007-2020: NIH Peer Review Committee NIH, (NAIID) Allergy, Immunology and Transplantation Research Committee (AITRC), 2007-2010; Inflammation and Innate Immunity study section (III), 2011; Arthritis, Connective Tissue, Skin (ACTS) study section, ad-hoc member, 2009-2011; RC1 challenge grant review committee, ZRG1 MOSS-C58, Cellular and Molecular Immunology (CMIA), 2012, and AMS, 2012; Inflammation and Innate Immunity (III), 2012-13, ZRG1 MOSS-D (02); Chair, Lupus animal model, ACR, 2012-14, 2013/01 ZRG1 IMM-D (02) M, 2012; Cellular and Molecular Immunology (CMIA, 2013, 2014); Inflammation and Innate Immunity study section (III), 2013; NIH Directors early independence awards, (DP5) 2014, 2014/10 ZRG1 IMM-K; AREA: Immunology, 2014/10 ZRG1 F07-K (20); Fellowship: Immunology, IHD, 2015, ZRG1 IMM-H (02)M, 2015, 2016-2017; Immunology Fellowship, 2016, 2012-2016, Inflammation and Innate Immunity ( III) 2017, 2018; Autoimmunity Center of Excellence (ACE), 2018, 2019.

Arthritis Foundation, cellular immunology, Member; Italian Ministry of Health grants. 2010/05 Member, Spanish Catalan Agency for Health Technology Assessment and Research (CAHTA), Member, Swiss National Science Foundation, 2010-2011, Ph.D. Thesis examiner, BHU, AIIMS, New Delhi, 2012-2017.

Journal Editorial Boards

Consulting Reviewer 2007-2020:

J Immunol, PNAS, Autoimmunity, Arthritis Rheum, Cellular Immunology, Clinical Immunol, International Journal of Artificial Organs, Alimentary Pharmacology & Therapeutics, J of Stem cells, International journal of Probiotics and Prebiotics, J of Clinical Experimental Medicine, Biomarkers and Molecular Biology Reports, J of Clinical Rheumatology, J of Molecular Immunology, Kidney International, J of Molecular and Cellular Biology, Arthritis Research & Therapy, PLoS ONE, Inflammation Research, Clinical and Experimental Immunology, Biomolecules. Neuroreport, and Lupus.

Associate Editor: International Journal of Rheumatic Diseases

PATENTS

1. UCLA Case No. 2008-211-2, “Peptide for Induction of Immune Tolerance as Treatment for Systemic Lupus Erythematosus”, September 19, 2007 (Co-Inventors: BH Hahn, FM Ebling, A La Cava, RR Singh, RP Singh). Publication No. US-201*-*******-A1, Publication Date 09/16/2010.

2. UCLA Case No. 2010-712, “Peptides for Oral Treatment of Systemic Lupus Erythematosus”, (Co-Inventors: BH Hahn, B Skaggs, A La Cava, RP Singh, RR Singh FM Ebling).

3. Singh RP, Hahn BH. “Interferon Genes as Biomarkers for Lupus, Inflammation and Autoimmunity”. UCLA Case # 2011-650.

4. Singh RP, DS Bischoff, K Uyemura, MK Song, DT Yamaguchi. “Composition and Methods for Treating and Preventing Immune Deficiency and Inflammation”. VAGLAHS Case # 2016-040.

PUBLICATIONS

More than 30 peer-reviewed publications. Complete List in My Bibliography:

http://www.ncbi.nlm.nih.gov/sites/myncbi/1JUzfueTrXukf/bibliography/48420109/public/?sort=date&direction=ascending

Selected Publications:

1. Functional genomics: At UCLA, I explored how the genome affects brain structure in both health and disease. To achieve this goal, I developed technologies for high throughput multi-modality acquisition of brain gene expression patterns and mapped the expression pattern of Thy1, MBP (myelin basic protein), and D2R genes. This work led to 6 peer-reviewed publications including:

a. Singh RP, Brown VM, Chaudhary A, Khan AH, Ossadtchi A, Sforza DM, Meadors AK, Cherry SR, Leahy RM, Smith DJ. High-resolution voxelation mapping of human and rodent brain gene expression. Journal of Neuroscience Methods. 125:(1-2):93-101, 2003. [Cover article] PMID: 12763235. Cited 25 times.

b. Liu D, Singh RP, Khan AH, Lusis AJ, Davis RC, Smith DJ. Identifying Loci for Behavioral Traits using Genome-Tagged Mice. Journal of Neuroscience Res. Nov; 74(4):562-9, 2003. PMID: 14598300. Cited 19 times.

c. Singh RP. Liu D, Chaudhary A, Cherry SR, Leahy RM, Smith DJ. Investigation of different transcript quantitation tools for high-throughput mapping of brain gene expression using voxelation. J of Molecular Histology, 35(4):397-402, 2004. [Cover article]. PMID:15503813.

d. Liu D, Singh RP, Khan AH, Lusis AJ, Davis RC, Smith DJ. Mapping behavioral traits using genetically tagged mice. American J of Geriatric Psychiatry. March-April 12(2):158-65, 2004. (Equal contributions, Liu and Singh). PMID: 15010345. Cited 14 times

2. Immunomodulatory effect of medicinal plants: During my Ph.D., I studied the various clinical, biochemical, pharmacological, and immunological effects of natural plant based immune-modulators as novel therapeutic agents for renal failure in experimental animal models (mice and rats) and in humans. These studies showed for the first time the protective role of these immunomodulators in patients with chronic renal failure (such as nephrotic syndrome) in terms of an increased level of immunoglobulins, reduced immune complexes, and improved renal function tests. The studies lead to 7 presentations (two at international meetings) and 7 peer-reviewed publication including:

a. Singh RP, Singh RG, Usha, Shukla KP, Udupa KN. Biochemical and histopathological effect of Boerhavia diffusa and Tribulus terrestris induced diuretics in rats. Alternative Medicine (International Journal). 3(3):165-72, 1990.

b. Singh RP, Singh RG, Usha, Shukla KP, Singh P. Experimental evaluation of diuretic action of herbal drug Tribulus terrestris on albino rats. J Res Edu Med, (International Quarterly Journal). X, 1:19-21, 1991.

c. Singh RP, Singh RG, Usha, Pandey BL, Singh RH. Experimental evaluation of diuretic action of herbal drug Trinapanchmula. J Res Edu Ind Med (International Quarterly Journal). X 4, 35-39, 1991.

d. Singh RP, Shukla KP, Pandey BL, Singh RG, Usha, Singh RH. Recent approach in clinical and experimental evaluation of diuretic action of Punarnava with special reference to nephrotic syndrome. J Res Edu Ind Med (International Quarterly Journal). XI, 29-36, 1992.

3. Investigating the role of cytokines in immune regulation and infectious diseases: During my post- doctoral training, I studied the role of cytokines (Th1 inducing cytokines IL-12 and IL-18) in host protection against M. leprae infection using genetically resistant and susceptible mice. I investigated the molecular mechanisms responsible for cytokine gene regulation in vivo and possible protective role of cytokines (IL-12 and IGIF) in controlling mycobacterial infections. At the University of Tokyo, Japan with Prof. Kiyoshi Takatsu, I studied the role of the TCR-V-α and V-β genes in infection. The group developed many clones, which often expressed Vβ11+ T cells after interaction with peptide 25 of α antigen (M.tb). I cloned the gene for V-α and V-β of TCR and sequenced the gene in order to understand the full-length V- β, and to uncover genetic mutations. Our aim was to make transgenic mice of peptide 25-reactive TCR Vβ+11+ T cell. As a result of my work, transgenic KO mice were made at Tokyo University and are being explored for TB vaccines. In addition, I described for the first time the protective role of IL-18 in blood stage malaria infections and addressed the mechanisms of protection using various cellular and molecular approaches. At University of California, Los Angeles, I demonstrated the effect of HLA class I monoclonal antibodies (W6/32) to investigate the potential genes involved in transplant rejection and the role of immunosuppressive drugs. These studies lead to 4 presentations (including two at international meetings) and 4 peer-reviewed publications:

a.Kobayashi K, Gidoh M, Kai M, Singh RP, Hashimoto K, Saito H. The rational basis of interleukin-12 immunotherapy for established Mycobacterial infection in mice. Thirty-third research conference on tuberculosis and leprosy. U.S.-Japan Cooperative Medical Science Program, Osaka, 184-188, 1998.

b. Kobayashi K, Kai M, Gidoh M, Nakata N, Endoh M, Singh RP, Kasama T, Saito H. The possible role of Interleukin (IL)-12 and Interferon-g-inducing factor/IL-18 in protection against experimental M. leprae infection in mice. Clinical Immunol Immunopathol. 88(3):226-231, 1998. PMID: 9743608. Cited 72 times.

c. Singh RP, Kashiwamura S, Rao P, Okamura H, Mukherjee A, Chauhan VS. The role of IL-18 in Blood–Stage Immunity Against Murine Malaria Plasmodium yoelii 265 and Plasmodium berghei ANKA. J Immunol. 168:4674-4681, 2002. PMID: 11971017 Cited 70 times.

d. Jin YP, Singh RP, Du ZY, Rajasekaran AK, Rozengurt E, Reed EF. Ligation of HLA Class I Molecules on Endothelial cells Induces Phosphorylation of Src, paxillin, and Focal Adhesion Kinase in an actin Dependent Manner. J Immunol. 168:5415-23, 2002. PMID: 12023334. Cited 107times.

4. Molcular immunoregulation of Treg, miRNAs and stem cells: I studied the role of Treg in regulation of autoimmunity. Further, I investigated the role of sex differences in the expression and function of Treg in systemic lupus erythematosus SLE. I also investigated the role of candidate miRNAs in lupus and rheumatoid arthritis and how they regulate T reg and apoptosis in autoimmunity. Recently, I studied the immunomodulatory effect of human mesenchymal stem cells in lupus. These studies led to national and international presentations, two patent applications, and several publications including:

a. Lourenço EV, Procaccini C, Ferrera F, Iikuni I, Singh RP, Filaci G, Giuseppe Matarese, Shi FD, Brahn E, Hahn BH, La Cava A. Critical role of p38 in adaptive regulatory T cells induced by anti-DNA Ig peptide in (NZB x NZW) F1 lupus mice. J Immunol, 182(12):7415-21, 2009. PMC2758643. Cited 14 times.

b. Wong M, La Cava A, Singh RP, Hahn BH. Blockade of Programmed Death-1 (PD-1) in young (New Zealand Black x New Zealand White) F1 mice promote the activity of suppressive CD8+ T cells that protect from lupus-like disease. J Immunol. 185(11):6563-71, 2010. PMID: 21041733. Cited 30 times.

c. Singh RP, Dinesh R, Elashoff D, Rooney R, Patel D, Sven De Vos, La Cava A, Hahn BH. Tolerization of BWF1 lupus mice with pConsensus peptide results in a distinct gene signature in WBC, CD4+ and CD8+ T cells. Genes and Immunity, 11:294–309, 2010, PMID: 20200542. Singh is the corresponding author. Cited 16 times.

d. Kimbrel EA,Kouris NA, Yavanian G, Chu J, Quinn C, Chan A, Singh RP, Mc Curdy D, Gordon L, Levinson RD, Lanza R. Mesenchymal stem cells generated from hESC-derived hemangioblasts display potent immunomodulatory and therapeutic properties. Stem Cell and Development, 23(14):1611-24, 2014. PMID: 24650034. PMCID: PMC 4086362. Cited 1116 times.

e. Katsiougiannis S, Chia D, Kim Y, Singh RP, Wong DT. Saliva exosomes from pancreatic tumor-bearing mice modulate NK cell phenotype and antitumor cytotoxicity. FASEB J, 31(3):998-1010, 2017. PMID: 27895106. PMCID: PMC5295729. Cited 15 times.

f. Singh RP, Hahn BH. Sex hormones and gender influence the expression and function of regulatory T cells in SLE. May1, 2018-200 (1)-175.5, Submitted to J Immunol. Singh is the corresponding author. Cited 4 times

5. Immune Regulation; Role of CD8+ Foxp3 regulatory T cells in immune tolerance (Lupus): We were the first to show that pCons peptide induces CD8+ Foxp3+ regulatory T cells which protects lupus mice. Further, we demonstrated that this protection depends in part on the generation of peripheral TGFβ and Foxp3-expressing inhibitory CD8+ (Ti) cells. These CD8+ T suppressor cells suppressed anti-DNA IgG production both in vitro and in vivo and required up-regulated expression of both Foxp3 and TGFβ to exert their suppressive function, as indicated by microarray analyses, small interfering RNA inhibition studies, and blocking experiments. Additionally, CD8+ T regulatory cells from pCons-tolerized mice were longer-lived suppressors that up-regulated expression of Bcl-2 and were more resistant to apoptosis than similar cells from naive mice. We have two US patents related to this project and several publications including:

a. Hahn BH, Singh RP, La Cava A, Ebling FM. Tolerogenic Treatment of Lupus Mice with Consensus Peptide Induces Foxp3-expressing, Apoptosis-resistant, TGFb-secreting CD8+ T cells Suppressors. J Immunol, 175:7728-7737, 2005. PMID: 16301683. Cited 128 times.

b. Singh RP, La Cava A, Wong M, Ebling F, Hahn BH. CD8+ T Cell mediated Suppression of Autoimmunity in a Murine Lupus Model of Peptide-Induced Immune Tolerance Depends on Foxp3 Expression. J Immunol, 178(12):7649-57, 2007. PMID: 17548601. Cited 89 times.

c. Singh RP, La Cava A, Hahn BH. pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZBX NZW) F1 mice by differentially regulating Foxp3 and PD1 molecules. J Immunol, 180:2069-80, 2008. PMID: 18250412. Singh is the corresponding author. Cited 49 times.

d. Dinesh R, Hahn BH, La Cava A, Singh RP. Interferon-inducible gene 202b controls CD8+ T cell-mediated suppression after anti-DNA Ig peptide treatment of (NZB x NZW) F1 lupus mice. Genes & Immunity, 4:1-10, 2011. PMID: 21326316. Singh is the corresponding author. Cited 7 times.

e. Singh RP, Hasan S, Nagra S, Sherven Sharma, Dean T, Yamaguchi, David Wong, Bevra H Hahn, Hossain A. Th17 cells in inflammation and autoimmunity. Autoimmunity, 13(12):1174-81, 2014. PMID: 25151974. Singh is the corresponding author. Cited 148 times

REVIEWS

1. Singh RP, Hahn BH, La Cava A. Tuning immune suppression in systemic autoimmunity with self-derived peptides. Inflammation &Allergy: Drug Targets, 7:253-259; 2008. Cited 12 times

2. Skaggs BJ, Singh RP, Hahn BH. Induction of immune tolerance by activation of CD8+T suppressor/regulatory cells in lupus-prone mice. Human Immunology, 69(11):790-796, 2008. Cited 23 times

3. Hahn BH, Singh RR, Singh RP, Wong M, Skaggs BJ, Tsao BP, La Cava A. Cellular regulation of autoimmunity, The ACR 75th Anniversary Diamond Jubilee, 21:125-131, 2009.

4. Dinesh RK, Skaggs BJ, La Cava A, Hahn BH, Singh RP. CD8+ Tregs in Lupus, Autoimmunity, and Beyond, Autoimmunity Review, 9(8):560-8, 2010. Singh is the corresponding author. Cited 95 times

5. Dinesh RK, Hahn BH, Singh RP. PD-1, gender, and autoimmunity. Autoimmunity Review, 9(8):583-587, 2010. Singh is the corresponding author. Cited 57 times

6. Sawla P, Hossain A, Hahn BH, Singh RP. Regulatory T cells in Systematic Lupus Erythematosus (SLE); Role of Peptide Tolerance. Autoimmunity Review, 11(9):611-4, 2012. Cited 34 times

7. Singh RP, Waldron R, Hahn BH. Genes, Tolerance and Systemic Autoimmunity. Autoimmunity Review, 11(9):664-9, 2012. Singh is the corresponding author.

Cited 29 times

8. Singh RP, Massachi I, Manickavel S, Singh S, Rao, NP, Hasan S, Mc Curdy D, Sharma, S, Wong, D, Hahn, BH, Rehimi, H. The role of miRNA inflammation and autoimmunity. 12:1160-5, 2013. Cited 178 times

9. Singh RP, Hasan S, Nagra S, Sherven Sharma, Dean T, Yamaguchi, David Wong, Bevra H Hahn, Hossain A. Th17 cells in inflammation and autoimmunity. Autoimmunity Review, 13(12):1174-81, 2014. Singh is the corresponding author.

Cited 148 times

CURRENT FUNDING

Neuro- bio LTD. (Cole), PI, 03/18/17 - 08-/30/20

Validation of biomarker to confirm the presence and extent of elevation of

Neuro- bio’s peptide (T14) in Alzheimer Disease brains by multiple methods.T14

is a peptide derived from the C-terminus of the tailed form of acetylcholinesterase that is

believed to bind alpha 7 nicotinic receptor and cause excitotoxic calcium flux and

inhibition of neuroprotective functions.

Role: Consultant- Investigator

VA Merit Review (Tache): PI 08/01/17- 06/30/21

Mechanisms and Therapeutic Intervention of Postoperative Ileus. This proposal seeks to analyze the phenotypic and functional characterization of M1/M2 macrophages and identification of candidate miRNAs and determination of their biological role in gut inflammation and mucosal immune system.

Role: Consultant

PENDING GRANTS Directs cost/year:

1 R01 AI126894-01A1, Singh RP (Principal Investigator). Role of Estradiol-Induced Genes in SLE, 07/01/ 2019-06/30/2024, Pending. $250,000/year.

1 R01 AI138480-01, Singh, RP (PI). Mechanisms of T cell (CD8+ Treg) Tolerance in Lupus and Regulation of Inflammation in SLE, 12/01/ 2019-11/30/2024, Pending, 250,000/year.

1 R21 AI149406-01, Singh Ram P. (PI). Role of miRNA in the Regulation of Apoptosis in Systemic Lupus Erythematosus. 10/01/2019-09/30/2021. Pending $ 275,000/year.

1 R21 AI147135-01; Singh Ram P, (PI). Disrupting TLR-9 Amplification in Lupus by Controlling Structure of DNA Immunocomplexes. 10/01/2019-09/30/2021. Pending, $275,000/year.

COMPLETE RESEARCH SUPPORT

Cure Parkinson Trust: ( Talbot, PI); 11/01/17-04/01/2019

Testing Dual And Triple Glucagon Family Receptor Agonists As Parkinson’s Disease Therapeutics.

Role: Investigator.

271201300029C-2-0-1 NIH (Nagra, PI): 09/01/13- 08/30/17.

NIMH, NICHD, AND NINDS Brain and Tissue Repository.

Role: Investigator.

BMS (Hahn): PI, 08/01/2015- 06/31/2018

Efficacy of Abatacept in Inflammatory Polyarthritis of Systemic Lupus Erythematosus (SLE).

Role: Co-Investigator

5 R21AI083894-02 Singh, RP (Principal Investigator) 07/22/09-06/30/12.

“Role of Sex Differences in the Expression & Function of Regulatory T cells in SLE”.

The goal was to explore the role of sex differences in the expression and function of Treg in SLE.

5 R03 AR054034-03 Singh, RP (Principal Investigator) NIH/NIAMS 08/21/07-07/31/11

“Delineating the Role of Selected Genes in Lupus Induced by CD8+Ti and CD4+CD25+ T reg Cells” The goal was to explore the molecular mechanisms that govern the suppression of autoimmunity.

5 R01 AR053239-05 La Cava (Principal Investigator) 08/01/06-06/30/12 NIH/NIAMS

Role: Co-Investigator. “Role of Leptin in Systemic Lupus Erythematosus”. The goal was to understand the role of leptin in SLE.

5 R21 AI065645-02 Singh, RP (Principal Investigator) 09/30/07-08/31/10.

NIH/NAIID: “Molecular Basis of Suppression of SLE by CD8+Ti Cells”

The goal of this project was to explore the suppression of autoimmunity in tolerized lupus mice by studying targeting genes differently expressed by CD8+ inhibitory T cells (Ti) from tolerized mice compared to naïve.

5 R37 AI046776:10 Hahn (PI) 05/01/05-01/31/11. NIH/NIAID: “Mechanism of Immune Tolerance Induced in Murine Lupus”. This proposal aims to define mechanisms of T cell tolerance induced in vivo in NZB/NZW F1 lupus mice by administration of a novel, artificial peptide (consensus peptide, pCONS). Role: Co-Investigator.

Lupus Foundation of America McCurdy (PI) 10/01/07- 10/15/10.

Pathways of autoimmunity linking polymorphisms in genes regulating the IFN-a pathway.

Role: Co -investigator.

Seattle Genetics; Singh RP, (Principal Investigator) ; 07-01-2007-12/31 2012. Characterization of cells from patients with rheumatoid arthritis or systemic lupus erythematosus.

American Autoimmune Related Disease Association; Singh RP (Principal Investigator). 12/01/10-11-30/13.

The goal was to explore the role of sex hormones in the

Contact this candidate